Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBIT (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBIT for 16 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 63.6% to $6.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.0 million, a 113.12% increase, with the full-year FY2024 number at $16.2 million, up 124.04% from a year prior.
  • EBIT was $6.9 million for Q3 2025 at Gyre Therapeutics, up from $126000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $51.5 million in Q2 2022 to a low of -$91.6 million in Q4 2023.
  • A 5-year average of -$6.5 million and a median of $665000.0 in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 342.74% in 2021, then soared 618.14% in 2023.
  • Gyre Therapeutics' EBIT stood at -$20.3 million in 2021, then tumbled by 98.27% to -$40.3 million in 2022, then crashed by 127.52% to -$91.6 million in 2023, then surged by 100.73% to $665000.0 in 2024, then surged by 941.35% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBIT are $6.9 million (Q3 2025), $126000.0 (Q2 2025), and $2.3 million (Q1 2025).